An investigation led by Brigham and Women's Hospital finds empagliflozin (sold as Jardiance) may reduce the risk of diabetic retinopathy (DR) progression in patients with a history of nonproliferative diabetic retinopathy (NPDR) but showed no association with preventing new NPDR onset.
from Medical Xpress - latest medical and health news stories https://ift.tt/z2UswW9
